168 related articles for article (PubMed ID: 35763235)
1. Intragastric Balloon in Obese Compensated Nonalcoholic Steatohepatitis Cirrhosis Patients Is Safe and Achieves Significant Weight Reduction at 6-Months.
Vijayaraghavan R; Sarin SK; Bharadwaj A; Anand L; Maiwall R; Choudhury A; Benjamin J; Kanal U; Jamwal KD
Dig Dis Sci; 2023 Mar; 68(3):1035-1041. PubMed ID: 35763235
[TBL] [Abstract][Full Text] [Related]
2. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
Bazerbachi F; Vargas EJ; Rizk M; Maselli DB; Mounajjed T; Venkatesh SK; Watt KD; Port JD; Basu R; Acosta A; Hanouneh I; Gara N; Shah M; Mundi M; Clark M; Grothe K; Storm AC; Levy MJ; Abu Dayyeh BK
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):146-154.e4. PubMed ID: 32360804
[TBL] [Abstract][Full Text] [Related]
3. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis.
Salomone F; Currenti W; Magrì G; Boškoski I; Zelber-Sagi S; Galvano F
Liver Int; 2021 Sep; 41(9):2112-2116. PubMed ID: 33938630
[TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
5. Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.
van Dijk AM; de Vries M; El-Morabit F; Bac ST; Mundt MW; van der Schuit LE; Hirdes MMC; Kara M; de Bruijne J; van Meer S; Kaasjager HAH; de Valk HW; Vleggaar FP; van Erpecum KJ
Intern Emerg Med; 2023 Nov; 18(8):2271-2280. PubMed ID: 37700180
[TBL] [Abstract][Full Text] [Related]
6. Fluid-filled intragastric balloons are an effective and safe weight loss option across BMI and age ranges.
Marrero Torres RJ; Gregory F; Micames CG
Surg Endosc; 2022 Jul; 36(7):5160-5166. PubMed ID: 34845556
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation.
Watt KD; Heimbach JK; Rizk M; Jaruvongvanich P; Sanchez W; Port J; Venkatesh SK; Bamlet H; Tiedtke K; Malhi H; Acosta Cardenas A; Grothe K; Clark M; Mundi MS; Abu Dayyeh BK
Liver Transpl; 2021 Sep; 27(9):1239-1247. PubMed ID: 33866660
[TBL] [Abstract][Full Text] [Related]
8. Intragastric Balloon Treatment for Obesity: Review of Recent Studies.
Tate CM; Geliebter A
Adv Ther; 2017 Aug; 34(8):1859-1875. PubMed ID: 28707286
[TBL] [Abstract][Full Text] [Related]
9. Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight Loss.
Agnihotri A; Xie A; Bartalos C; Kushnir V; Sullivan S; Islam S; Islam E; Lamet M; Lamet A; Farboudmanesch R; Overholt BF; Altawil J; Early DS; Bennett M; Lowe A; Mullady DK; Adeyeri CS; El Zein M; Mishra P; Fayad L; Dunlap M; Oberbach A; Cheskin LJ; Kalloo AN; Khashab MA; Kumbhari V
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1081-1088.e1. PubMed ID: 29481969
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis.
Chandan S; Mohan BP; Khan SR; Facciorusso A; Ramai D; Kassab LL; Bhogal N; Asokkumar R; Lopez-Nava G; McDonough S; Adler DG
Obes Surg; 2021 Mar; 31(3):1271-1279. PubMed ID: 33409973
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis.
Popov VB; Thompson CC; Kumar N; Ciarleglio MM; Deng Y; Laine L
Dig Dis Sci; 2016 Sep; 61(9):2477-87. PubMed ID: 27207181
[TBL] [Abstract][Full Text] [Related]
12. Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population.
Vargas EJ; Pesta CM; Bali A; Ibegbu E; Bazerbachi F; Moore RL; Kumbhari V; Sharaiha RZ; Curry TW; DosSantos G; Schmitz R; Agnihotri A; Novikov AA; Pitt T; Dunlap MK; Herr A; Aronne L; Ledonne E; Kadouh HC; Cheskin LJ; Mundi MS; Acosta A; Gostout CJ; Abu Dayyeh BK
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1073-1080.e1. PubMed ID: 29425781
[TBL] [Abstract][Full Text] [Related]
13. Comparative Study of Intragastric Balloon and Cognitive-Behavioral Approach for Non-Morbid Obesity.
Majanovic SK; Ruzic A; Bulian AP; Licul V; Orlic ZC; Stimac D
Hepatogastroenterology; 2014 Jun; 61(132):937-41. PubMed ID: 26158145
[TBL] [Abstract][Full Text] [Related]
14. Does Intragastric Balloon Treatment for Obesity in Chronic Kidney Disease Heighten Acute Kidney Injury Risk?
MacLaughlin HL; Macdougall IC; Hall WL; Dew T; Mantzoukis K; Oben JA
Am J Nephrol; 2016; 44(6):411-418. PubMed ID: 27784008
[TBL] [Abstract][Full Text] [Related]
15. Intragastric Balloon for Overweight Patients.
Martins Fernandes FA; Carvalho GL; Lima DL; Rao P; Shadduck PP; Montandon ID; de Souza Barros J; Rodrigues IL
JSLS; 2016; 20(1):. PubMed ID: 26955259
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting.
Swei E; Almuhaidb A; Sullivan S; Al-Shahrani A; D'Souza FR; Altayar O; Bell S; Maday R; Wagh MS; Mullady D; Bennett M; Early D; Kushnir V
J Clin Gastroenterol; 2023 Jul; 57(6):578-585. PubMed ID: 35604348
[TBL] [Abstract][Full Text] [Related]
17. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.
Lee YM; Low HC; Lim LG; Dan YY; Aung MO; Cheng CL; Wee A; Lim SG; Ho KY
Gastrointest Endosc; 2012 Oct; 76(4):756-60. PubMed ID: 22840293
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Intragastric Balloon Therapy Compared to a Multidisciplinary Weight Loss Program (OPTIFAST) in a Real-World Population: A Propensity Score Matching Analysis.
Oster M; Hein N; Aksan A; Krammer H; Theodoridou S; Stein J
Obes Facts; 2023; 16(1):89-98. PubMed ID: 36257288
[TBL] [Abstract][Full Text] [Related]
19. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.
Berzigotti A; Albillos A; Villanueva C; Genescá J; Ardevol A; Augustín S; Calleja JL; Bañares R; García-Pagán JC; Mesonero F; Bosch J;
Hepatology; 2017 Apr; 65(4):1293-1305. PubMed ID: 27997989
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria.
Jindal A; Sharma S; Agarwal S; Kumar M; Saraya A; Sarin SK
Hepatol Int; 2022 Feb; 16(1):89-98. PubMed ID: 35072932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
